MARKET

CLGN

CLGN

Collplant
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.20
-0.13
-1.39%
Closed 16:00 12/03 EST
OPEN
9.74
PREV CLOSE
9.33
HIGH
9.74
LOW
8.95
VOLUME
13.95K
TURNOVER
--
52 WEEK HIGH
14.55
52 WEEK LOW
4.900
MARKET CAP
60.47M
P/E (TTM)
-233.5025
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
How Should Investors Feel About CollPlant Biotechnologies' (NASDAQ:CLGN) CEO Remuneration?
Simply Wall St. · 1d ago
CollPlant EPS misses by $1.79, misses on revenue
CollPlant (CLGN): Q3 Non-GAAP EPS of $0.11 misses by $1.79; GAAP EPS of $0.07.Revenue of $4.1M (+502.9% Y/Y) misses by $16.99M.Press Release
Seekingalpha · 2d ago
CollPlant Biotechnologies Reports Third Quarter (Q3) 2020 Financial Results and Provides Business Update
CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the third quarter ended September 30, 2020 and provided an update on the Company's business developments. Certain metrics, including those expressed on an adjusted basis, are non-GAAP measures. See "Use of Non-GAAP Measures" below.
PR Newswire · 2d ago
CollPlant Announces Early Development Program of Antiviral Agent for Potential Treatment of COVID-19 Patients
REHOVOT, , /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative medicine company, today announced its development program of an antiviral agent for potential treatment of COVID-19 patients. early results of CollPlant's formulations showed significant inhibition of avian coronavirus infectivity. CollPlant's formulations designed for the potential treatment of COVID-19 patients are based on CollPlant's proprietary recombinant human type I collagen (rhCollagen) imbedded with silver nanoparticles (AgNP).
PR Newswire - PRF · 11/10 12:00
CollPlant Announces Early Development Program of Antiviral Agent for Potential Treatment of COVID-19 Patients
CollPlant (NASDAQ: CLGN) a regenerative medicine company, today announced its development program of an antiviral agent for potential treatment of COVID-19 patients. In-vitro early results of CollPlant's formulations showed significant inhibition of avian coronavirus infectivity. CollPlant's formulations designed for the potential treatment of COVID-19 patients are based on CollPlant's proprietary recombinant human type I collagen (rhCollagen) imbedded with silver nanoparticles (AgNP).
PR Newswire · 11/10 12:00
CollPlant Receives Substantial First Order for its Vergenix Flowable Gel Product in Ukraine
CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that it has received a substantial first order totaling hundreds of thousands of U.S. dollars for its Vergenix™ Flowable Gel (FG) product in Ukraine from CollPlant's new distribution partner, a Russia-based biopharmaceutical company. CollPlant will begin shipments in the current quarter.
PR Newswire · 10/26 12:00
CollPlant receives substantial first order for its Vergenix™ FG in Ukraine
Vergenix™flowable gel is based on the CollPlant's (CLGN) rhCollagen technology and is a wound-care product designed to treat acute and chronic hard-to-heal wounds, such as diabetic ulcers, pressure sores, surgical
Seekingalpha · 10/26 11:14
CollPlant Receives Substantial First Order for its Vergenix™ Flowable Gel Product in Ukraine
REHOVOT, Israel , Oct. 26, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that it has received a substantial first order totaling hundreds of thousands of U.S. dollars for its Vergenix ™  Flowable Gel (FG) product in Ukraine from CollPlant's new distribution partner, a Russia -based biopharmaceutical company. CollPlant will begin shipments in the current quarter.
PR Newswire · 10/26 11:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLGN. Analyze the recent business situations of Collplant through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLGN stock price target is 14.00 with a high estimate of 15.00 and a low estimate of 13.00.
EPS
Institutional Holdings
Institutions: 8
Institutional Holdings: 890.52K
% Owned: 13.56%
Shares Outstanding: 6.57M
TypeInstitutionsShares
Increased
4
251.06K
New
1
10.97K
Decreased
1
422
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.41%
Pharmaceuticals & Medical Research
+0.49%
Key Executives
Chairman/Independent Director
Roger Pomerantz
Chief Executive Officer
Yehiel Tal
Deputy Chief Executive Officer/Chief Financial Officer/IR Contact Officer
Eran Rotem
Chief Operating Officer
Ilana Belzer
Vice President
Philippe Bensimon
Vice President - Research & Development
Nadav Orr
Other
Oded Shoseyov
Non-Executive Director
Gili Hart
Non-Executive Director
Elan Penn
Independent Director
Abraham Havron
Other
Dana Gottesman Erlich
Other
Revital Mandil-Levin
Independent Director
Joseph Zarzewsky
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CLGN
CollPlant Biotechnologies Ltd is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Collplant Biotechnologies Ltd - ADR stock information, including NASDAQ:CLGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLGN stock methods without spending real money on the virtual paper trading platform.